Published in AIDS Weekly, June 3rd, 2002
The vaccines are being built from a technology, Semliki Forest virus (SFV) alphavirus replicons, pioneered by scientists at the Karolinska Institute in Sweden.
The nonprofit IAVI is financing and coordinating the research, with the goal of starting human testing of SFV-based AIDS vaccines within 2 years. Bioption and IAVI have agreed to use their joint ownership of any successful AIDS vaccines to provide them to developing countries...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.